首页> 美国卫生研究院文献>other >The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC)

【2h】

The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC)

机译：铂或吉西他滨（PG）联合或不联合分子靶向药物（MTA）化疗在非小细胞肺癌（NSCLC）一线治疗中的有效性和安全性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background:Trials investigating the efficacy and safety of combining molecular targeted agent (MTA) with platinum–gemcitabine (PG) in first-line treatment of advanced non-small cell lung cancer (NSCLC) have shown inconsistent findings. This meta-analysis aimed to explore whether the addition of MTAs to PG in NSCLC could provide a survival benefit with a tolerable toxicity.

机译：背景：关于将分子靶向药物（MTA）与铂-吉西他滨（PG）联合用于一线治疗晚期非小细胞肺癌（NSCLC）的功效和安全性的试验结果不一致。这项荟萃分析旨在探讨在NSCLC中向PG添加MTA是否可以提供生存耐受性并具有可耐受的毒性。

著录项

期刊名称 other
作者
Jiaying Yang; Jieyu He; Miao Yu; Taishun Li; Li Luo; Pei Liu;
展开▼
作者单位

展开▼
年(卷),期 -1(95),50
年度 -1
页码 e5599
总页数 10
原文格式 PDF
正文语种
中图分类
关键词
EGFR NSCLC platinum–gemcitabine targeted therapy;

机译：EGFR;NSCLC;铂-吉西他滨;靶向治疗;

相似文献

外文文献
中文文献
专利

1. The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC) [J] . Yang Jiaying, He Jieyu, Yu Miao, Medicine. . 2016,第50期

机译：铂加吉西他滨（PG）化疗联合或不联合分子靶向药物（MTA）在非小细胞肺癌（NSCLC）一线治疗中的有效性和安全性
2. The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC) [J] . Yang Jiaying, He Jieyu, Yu Miao, Medicine. . 2016,第50期

机译：铂加吉西他滨（PG）化疗与或不含分子靶向剂（MTA）的非小细胞肺癌（NSCLC）的疗效和安全性
3. Safety and Efficacy of Necitumumab (N) During Single-Agent Treatment to Progression Following Gemcitabine-Cisplatin (GC) Chemotherapy Plus Necitumumab (IMC-11F8/LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (sq-NSCLC) (SQUIRE) [J] . Socinski M. A., Thatcher N., Luft A. V., International Journal of Radiation Oncology, Biology, Physics . 2014,第5Suppla期

机译：吉西他滨-顺铂（GC）化疗加尼西妥单抗（IMC-11F8 / LY3012211）在IV期鳞状非小细胞肺癌患者的一线治疗中，单药治疗进展前尼西单抗的安全性和有效性（平方-NCLCL）（平方）
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. Pre-Treatment Radiomics Models for Clinical Outcomes in Early-Stage Non-Small Cell Lung Cancer (NSCLC) [D] . Shaffer, Nathan Allen. 2021

机译：早期非小细胞肺癌临床结果的预处理辐射瘤模型（NSCLC）
6. Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Meta-Analysis [O] . Fei Chen, Naifei Chen, Yu Yu, 2020

机译：表皮生长因子受体（EGFR）抑制剂加抗血管生成剂作为一线治疗的疗效和安全性的疗效和安全性用于高级EGFR突变的非小细胞肺癌的患者：META分析
7. The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC) [O] . Jiaying Yang, Jieyu He, Miao Yu, 2016

机译：铂加吉西他滨（PG）化疗与或不含分子靶向剂（MTA）的非小细胞肺癌（NSCLC）的疗效和安全性

The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC)

摘要

著录项

相似文献

相关主题

期刊订阅